Intravenous immunoglobulin treatment may benefit skin, musculoskeletal and gastrointestinal manifestations of systemic sclerosis, with low risks for adverse events, according to data published in Seminars in Arthritis and Rheumatism.“The use of IVIG in SSc was first reported in the early 2000s, when three patients showed marked skin thickness reduction after a 6-monthly course of IVIG,” Sasza Koczanowski, BBiomed, of the University of Melbourne, and colleagues wrote. “Subsequently, multiple studies have investigated the role of IVIG in SSc treatment, particularly in patients

View Entire Post